Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Year: 2019
Type: article
Source: Annals of Oncology
Institutions: University of California San Diego, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, Institut Gustave Roussy, Fondation Gustave Roussy, Institut Curie, Washington University in St. Louis, Hadassah Medical Center, Vall d'Hebron Institute of Oncology, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2991024603